AR062659A1 - Composicion de liberacion sostenida de levodopa y metodo para su uso - Google Patents
Composicion de liberacion sostenida de levodopa y metodo para su usoInfo
- Publication number
- AR062659A1 AR062659A1 ARP070103916A ARP070103916A AR062659A1 AR 062659 A1 AR062659 A1 AR 062659A1 AR P070103916 A ARP070103916 A AR P070103916A AR P070103916 A ARP070103916 A AR P070103916A AR 062659 A1 AR062659 A1 AR 062659A1
- Authority
- AR
- Argentina
- Prior art keywords
- levodopa
- subject
- composition
- interval
- hours
- Prior art date
Links
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title abstract 9
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title abstract 9
- 229960004502 levodopa Drugs 0.000 title abstract 9
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
- 230000002035 prolonged effect Effects 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 210000002438 upper gastrointestinal tract Anatomy 0.000 abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 230000001095 motoneuron effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Composiciones farmacéuticas que comprende levodopa y que, cuando se administra en una dosis unitaria de levodopa de alrededor de 100 hasta alrededor de 500 mg con un intervalo entre tomas de alrededor de 6 hasta alrededor de 24 horas, exhibe un período de liberacion suficientemente prolongado y un tiempo de residencia suficientemente prolongado en el tracto gastrointestinal alto para proporcional una concentracion mínima de levodopa en el plasma del sujeto que no es inferior a una concentracion umbral mínima por debajo de la cual se observan en el sujeto efectos motores adversos. También se proporciona un método para tratar la enfermedad de Parkinson en un sujeto, que comprende administrar por vía oral dicha composicion al sujeto en una dosis unitaria de levodopa de alrededor de 50 hasta alrededor de 1000 mg con un intervalo entre tomas de alrededor de 3 hasta alrededor de 24 horas. Reivindicacion 1: Una composicion farmacéutica que se puede administrar por vía oral y que comprende levodopa y al menos un excipiente adecuado para uso farmacéutico, caracterizada porque la composicion, cuando se administra por vía oral en una dosis unitaria de levodopa de alrededor de 100 hasta alrededor de 50 mg a un sujeto humano con un intervalo entre tomas de alrededor de 6 hasta alrededor de 24 horas, exhibe (a) un período de liberacion de levodopa suficientemente prolongado y (b) un tiempo de resistencia en el tracto gastrointestinal alto del sujeto suficientemente prolongado para proporcionar una concentracion mínima de levodopa en el plasma del sujeto que no es inferior a una concentracion umbral mínima de alrededor de 300 ng/ml.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82498506P | 2006-09-08 | 2006-09-08 | |
| US82827606P | 2006-10-05 | 2006-10-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062659A1 true AR062659A1 (es) | 2008-11-26 |
Family
ID=39157983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103916A AR062659A1 (es) | 2006-09-08 | 2007-09-05 | Composicion de liberacion sostenida de levodopa y metodo para su uso |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20080139655A1 (es) |
| AR (1) | AR062659A1 (es) |
| CL (1) | CL2007002574A1 (es) |
| PE (1) | PE20080669A1 (es) |
| WO (1) | WO2008030830A2 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2740360T3 (es) * | 2008-08-15 | 2020-02-05 | Assertio Therapeutics Inc | Composiciones farmacéuticas de retención gástrica para el tratamiento y la prevención de trastornos del SNC |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| PT3116475T (pt) | 2014-03-13 | 2020-12-15 | Neuroderm Ltd | Composições de inibidores de dopa-descarboxilase |
| CN110582271B (zh) * | 2017-03-01 | 2022-06-14 | 阿瑞那制药公司 | 包含pgi2受体激动剂的组合物及其制备方法 |
| CN109439645B (zh) * | 2018-10-31 | 2022-07-19 | 武汉工程大学 | 利用锐孔法制备解磷微生物缓释海藻酸钠微球的方法 |
| WO2020230089A1 (en) | 2019-05-14 | 2020-11-19 | Clexio Biosciences Ltd. | Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease |
| CN116234555A (zh) * | 2020-06-30 | 2023-06-06 | 安布里亚制药公司 | 改良形式的曲美他嗪的改良释放制剂 |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| WO2022195476A1 (en) | 2021-03-15 | 2022-09-22 | Clexio Biosciences Ltd. | Gastroretentive devices for assessment of intragastric conditions |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4424235A (en) * | 1981-09-14 | 1984-01-03 | Hoffmann-La Roche Inc. | Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor |
| ZA889189B (en) * | 1986-06-16 | 1989-08-30 | Merck & Co Inc | Controlled release combination of carbidopa/levodopa |
| US5190763A (en) * | 1990-05-07 | 1993-03-02 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
| IL133196A0 (en) * | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
| AU2001268722B8 (en) * | 2000-06-23 | 2005-09-29 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
| US6531153B2 (en) * | 2001-05-29 | 2003-03-11 | Drugtech Corporation | Composition with sustained release of levodopa and carbidopa |
| CA2409552A1 (en) * | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| US20030224045A1 (en) * | 2002-05-29 | 2003-12-04 | Chien-Hsuan Han | Combination immediate release sustained release levodopa/carbidopa dosage forms |
| CA2501345A1 (en) * | 2002-10-11 | 2004-04-22 | Depomed Development, Ltd. | Gastro-retentive levodopa delivery form |
| US20040185097A1 (en) * | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
-
2007
- 2007-09-05 AR ARP070103916A patent/AR062659A1/es unknown
- 2007-09-05 US US11/850,063 patent/US20080139655A1/en not_active Abandoned
- 2007-09-05 WO PCT/US2007/077572 patent/WO2008030830A2/en not_active Ceased
- 2007-09-05 CL CL200702574A patent/CL2007002574A1/es unknown
- 2007-09-05 PE PE2007001186A patent/PE20080669A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CL2007002574A1 (es) | 2008-05-23 |
| US20080139655A1 (en) | 2008-06-12 |
| WO2008030830A2 (en) | 2008-03-13 |
| WO2008030830A3 (en) | 2008-05-29 |
| PE20080669A1 (es) | 2008-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062659A1 (es) | Composicion de liberacion sostenida de levodopa y metodo para su uso | |
| ES2526648T3 (es) | Método para mejorar el estrés oxidativo y la memoria de trabajo mediante la administración de pterostilbeno | |
| PE20040134A1 (es) | Forma de dosificacion de una vez al dia de pramipexol | |
| ES2916604T1 (es) | Ensayos de detección de nrf2 y métodos y composiciones relacionados | |
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| AR070025A1 (es) | Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica | |
| MX2009003372A (es) | Formas de dosificacion de pelicula no mucoadhesiva. | |
| AR111572A2 (es) | Formas farmacéuticas que contienen vardenafilo | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| SG158870A1 (en) | Bendamustine pharmaceutical compositions for lyophilisation | |
| PE20060588A1 (es) | Composiciones farmaceuticas que contienen flibanserina | |
| ECSP10010052A (es) | Formulaciones galenicas de alisquireno y valsartan | |
| AR068185A1 (es) | Composiciones de tabletas de desintegracion oral de lamotrigina | |
| MX363023B (es) | Formulaciones orales de analogos de citidina y metodos para usar los mismos. | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| AR084816A1 (es) | Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer | |
| EA201170527A1 (ru) | Фармацевтические композиции, включающие соединения бороновой кислоты | |
| AR081254A1 (es) | Composicion farmaceutica que comprende ave0010 e insulina glargina | |
| BRPI0611705A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de composto | |
| CO6280475A2 (es) | Metodo para tratar la deficiencia de vitamina b12 | |
| AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| CA3019769C (en) | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa | |
| UY32109A (es) | Métodos para utilizar composiciones de liberación sostenida de aminopiridina | |
| AR095159A2 (es) | Una composición farmacéutica en forma de cápsula para administración oral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |